CervoMed Historical Financial Ratios
| CRVO Stock | 7.88 0.37 4.48% |
CervoMed is presently reporting on over 85 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, PTB Ratio of 0.46 or Days Sales Outstanding of 45.22 will help investors to properly organize and evaluate CervoMed financial condition quickly.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CervoMed. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. About CervoMed Financial Ratios Analysis
CervoMedFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate CervoMed investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on CervoMed financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across CervoMed history.
CervoMed Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing CervoMed stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on CervoMed sales, a figure that is much harder to manipulate than other CervoMed multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Most ratios from CervoMed's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into CervoMed current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CervoMed. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in CervoMed Stock, please use our How to Invest in CervoMed guide.At this time, CervoMed's Income Quality is very stable compared to the past year. As of the 24th of July 2025, Net Debt To EBITDA is likely to grow to 0.52, while Price To Sales Ratio is likely to drop 1.84.
| 2024 | 2025 (projected) | Interest Debt Per Share | 81.46 | 77.39 | Revenue Per Share | 1.21 | 1.15 |
CervoMed fundamentals Correlations
Click cells to compare fundamentals
CervoMed Account Relationship Matchups
High Positive Relationship
High Negative Relationship
CervoMed fundamentals Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Ptb Ratio | 1.74 | 0.87 | (0.12) | 2.75 | 0.48 | 0.46 | |
| Book Value Per Share | 34.57 | 26.82 | (64.24) | 2.77 | 4.86 | 5.1 | |
| Free Cash Flow Yield | (0.31) | (0.48) | (0.65) | (0.37) | (0.88) | (0.92) | |
| Operating Cash Flow Per Share | (18.88) | (11.14) | (4.97) | (2.8) | (2.05) | (2.15) | |
| Pb Ratio | 1.74 | 0.87 | (0.12) | 2.75 | 0.48 | 0.46 | |
| Free Cash Flow Per Share | (18.88) | (11.14) | (4.97) | (2.8) | (2.05) | (2.15) | |
| Net Income Per Share | (19.76) | (18.51) | (11.2) | (0.82) | (2.02) | (2.12) | |
| Payables Turnover | 0.19 | 0.0986 | 13.74 | 12.74 | 11.46 | 12.04 | |
| Cash Per Share | 25.8 | 28.67 | 31.85 | 2.93 | 4.82 | 4.58 | |
| Pocfratio | (3.18) | (2.09) | (1.53) | (2.73) | (1.14) | (1.2) | |
| Pfcf Ratio | (3.18) | (2.09) | (1.53) | (2.73) | (1.14) | (1.2) | |
| Days Payables Outstanding | 1.9K | 3.7K | 26.57 | 28.65 | 25.79 | 24.5 | |
| Roe | (0.57) | (0.69) | 0.17 | (0.29) | (0.42) | (0.44) | |
| Ev To Operating Cash Flow | (1.82) | (0.21) | (14.2) | (1.68) | (0.6) | (0.63) | |
| Pe Ratio | (3.04) | (1.26) | (0.68) | (9.35) | (1.16) | (1.22) | |
| Return On Tangible Assets | (0.68) | (0.64) | (1.4) | (0.22) | (0.38) | (0.4) | |
| Ev To Free Cash Flow | (1.82) | (0.21) | (14.2) | (1.68) | (0.6) | (0.63) | |
| Earnings Yield | (0.33) | (0.8) | (1.48) | (0.11) | (0.86) | (0.91) | |
| Net Debt To E B I T D A | 1.23 | 1.17 | 1.12 | 3.59 | 0.49 | 0.52 | |
| Current Ratio | 7.71 | 12.92 | 5.61 | 3.84 | 11.11 | 11.66 | |
| Tangible Book Value Per Share | 22.54 | 26.82 | (64.24) | 2.77 | 4.86 | 5.1 | |
| Shareholders Equity Per Share | 34.57 | 26.82 | (64.24) | 2.77 | 4.86 | 5.1 |
Pair Trading with CervoMed
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CervoMed position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CervoMed will appreciate offsetting losses from the drop in the long position's value.Moving against CervoMed Stock
| 0.74 | EC | Ecopetrol SA ADR | PairCorr |
| 0.68 | PFE | Pfizer Inc | PairCorr |
| 0.65 | PTAIF | PT Astra International Earnings Call This Week | PairCorr |
| 0.64 | MRVI | Maravai Lifesciences | PairCorr |
| 0.61 | VTYX | Ventyx Biosciences | PairCorr |
The ability to find closely correlated positions to CervoMed could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CervoMed when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CervoMed - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CervoMed to buy it.
The correlation of CervoMed is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CervoMed moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CervoMed moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CervoMed can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CervoMed. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in CervoMed Stock, please use our How to Invest in CervoMed guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CervoMed. If investors know CervoMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CervoMed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.17) | Revenue Per Share | Quarterly Revenue Growth (0.18) | Return On Assets | Return On Equity |
The market value of CervoMed is measured differently than its book value, which is the value of CervoMed that is recorded on the company's balance sheet. Investors also form their own opinion of CervoMed's value that differs from its market value or its book value, called intrinsic value, which is CervoMed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CervoMed's market value can be influenced by many factors that don't directly affect CervoMed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CervoMed's value and its price as these two are different measures arrived at by different means. Investors typically determine if CervoMed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CervoMed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.